iopamidol
Generic: IOPAMIDOL·Brand: IOPAMIDOL, IOPAMIDOL-200, IOPAMIDOL-200 IN PLASTIC CONTAINER, IOPAMIDOL-250, IOPAMIDOL-250 IN PLASTIC CONTAINER, IOPAMIDOL-300, IOPAMIDOL-300 IN PLASTIC CONTAINER, IOPAMIDOL-370, IOPAMIDOL-370 IN PLASTIC CONTAINER, ISOVUE-128, ISOVUE-200, ISOVUE-250, ISOVUE-300, ISOVUE-370, ISOVUE-M 200, ISOVUE-M 300, SCANLUX-300, SCANLUX-370
iopamidol: 1 clinical trial tracked.
iopamidol evidence translation
What we can confirm
1 tracked trial
No verified listed company relationship
What it means
AI will separate confirmed drug evidence from unknown company context.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
What is verified about iopamidol, and what remains unknown?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Clinical Trial Registry Records (1)
A Phase 1B Study of Infigratinib in Combination With Tamoxifen in Hormone Receptor Positive, HER2 Negative, FGFR Altered Advanced Breast Cancer
Primary endpoint: Number of Dose-limiting Toxicities (DLTs)
Interventionalopen4 targetStarted 2020-10Completion 2021-101 site · United StatesJennifer Lee Caswell-Jin